Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Coronavirus | Research

Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms

Authors: Wajiha Javed, Syed Hussain Baqar Abidi, Jaffer Bin Baqar

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

The population-based serosurveys are essential for estimating Coronavirus Disease-19 (COVID-19) burden and monitoring the progression of this pandemic. We aimed to assess the seroprevalence of SARS-CoV-2 antibodies and potential predictors of seropositivity in the Pakistani population.

Methodology

This population-based seroprevalence study includes consenting subjects from the workplaces (factories, corporates, restaurants, media houses, schools, banks, and hospitals) located in the urban areas of Karachi, Lahore, Multan, Peshawar, and Quetta. We analyzed each subject's serum sample for SARS-CoV-2-IgM and/or IgG antibodies using UNIPER IgG/IgM Rapid COVID-19 Testing Kit. The subject's demographics, exposure history, and symptoms experienced (in last 7 days) were also obtained. The collected data was analyzed using SPSS version 22.0.

Results

The overall seroprevalence of SARS-CoV-2 antibodies was 16.0% (2810/17,764). The total antibody seropositivity was higher in males than females (OR 1.22, 95% CI 1.110–1.340). The symptomatic subjects had 2.18 times higher odds of IgG seropositivity while 1.2 times for IgM seropositivity than the asymptomatic subjects. The multivariable logistic regression model showed that the odds of SARS-CoV-2 total antibody seroprevalence were affected by the number of dependents (OR = 1.077; 95% CI 1.054–1.099), apparent symptomology (OR = 1.288; 95% CI 1.011–1.643), close unprotected contact with a confirmed or probable case of COVID-19 (OR 2.470; 95% CI 2.164–2.819), traveling history (last 14 days) (OR = 1.537; 95% CI 1.234–1.914) and proximity with someone who traveled (OR = 1.534; 95% CI 1.241–1.896).

Conclusion

We found a reasonable seroprevalence of SARS-CoV-2 antibodies in the studied population. Several factors like the number of dependents, apparent symptoms, close unprotected contact with a confirmed or probable case of COVID-19, traveling history, and proximity with someone who traveled are associated with increased odds of SARS-CoV-2 antibody seropositivity.
Literature
2.
go back to reference Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2.CrossRef Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2.CrossRef
3.
go back to reference Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan. China JAMA. 2020;323(11):1061–9.CrossRef Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan. China JAMA. 2020;323(11):1061–9.CrossRef
4.
go back to reference Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497–506.CrossRef Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497–506.CrossRef
7.
go back to reference Younas A, Waheed S, Khawaja S, Imam M, Borhany M, Shamsi T. Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan. Transfus Apher Sci. 2020;59(6): 102923.CrossRef Younas A, Waheed S, Khawaja S, Imam M, Borhany M, Shamsi T. Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan. Transfus Apher Sci. 2020;59(6): 102923.CrossRef
8.
go back to reference Wang P, Anderson N, Pan Y, Poon L, Charlton C, Zelyas N. The SARS-CoV-2 outbreak: diagnosis, infection prevention, and public perception. Clin Chem. 2020;66(5):644–51.CrossRef Wang P, Anderson N, Pan Y, Poon L, Charlton C, Zelyas N. The SARS-CoV-2 outbreak: diagnosis, infection prevention, and public perception. Clin Chem. 2020;66(5):644–51.CrossRef
9.
go back to reference Wang W, Xu Y, Gao R, Lu R, Han K, Wu G. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843–4.PubMedPubMedCentral Wang W, Xu Y, Gao R, Lu R, Han K, Wu G. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843–4.PubMedPubMedCentral
14.
go back to reference Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42.CrossRef Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42.CrossRef
15.
go back to reference Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol Dis. 2020;1(83): 102437.CrossRef Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol Dis. 2020;1(83): 102437.CrossRef
16.
go back to reference Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, Wu K, Yang L, Liu X, Zhu C. Decreased T cell populations contribute to the increased severity of COVID-19. Clin Chim Acta. 2020;1(508):110–4.CrossRef Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, Wu K, Yang L, Liu X, Zhu C. Decreased T cell populations contribute to the increased severity of COVID-19. Clin Chim Acta. 2020;1(508):110–4.CrossRef
18.
go back to reference Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(8):911–9.CrossRef Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(8):911–9.CrossRef
19.
go back to reference Jing QL, Liu MJ, Zhang ZB, Fang LQ, Yuan J, Zhang AR, et al. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(10):1141–50.CrossRef Jing QL, Liu MJ, Zhang ZB, Fang LQ, Yuan J, Zhang AR, et al. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(10):1141–50.CrossRef
20.
go back to reference Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020;180(9):1156–63.CrossRef Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020;180(9):1156–63.CrossRef
21.
go back to reference Chughtai OR, Batool H, Khan MD, Chughtai AS. Frequency of COVID-19 IgG antibodies among special police squad Lahore, Pakistan. J Coll Physicians Surg Pak. 2020;30:735–9.CrossRef Chughtai OR, Batool H, Khan MD, Chughtai AS. Frequency of COVID-19 IgG antibodies among special police squad Lahore, Pakistan. J Coll Physicians Surg Pak. 2020;30:735–9.CrossRef
22.
go back to reference Younas A, Waheed S, Khawaja S, Imam M, Borhany M, Shamsi T. Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan. Transfus Apher Sci. 2020;59(60): 102923.CrossRef Younas A, Waheed S, Khawaja S, Imam M, Borhany M, Shamsi T. Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan. Transfus Apher Sci. 2020;59(60): 102923.CrossRef
23.
go back to reference Zaidi S, Rizwan F, Riaz Q, Siddiqui A, Khawaja S, Imam M, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi—challenges in acquiring herd immunity for COVID 19. J Pub Health. 2021;43(1):3–8.CrossRef Zaidi S, Rizwan F, Riaz Q, Siddiqui A, Khawaja S, Imam M, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi—challenges in acquiring herd immunity for COVID 19. J Pub Health. 2021;43(1):3–8.CrossRef
26.
go back to reference Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors. J Clin Med. 2020;9(9):2780.CrossRef Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors. J Clin Med. 2020;9(9):2780.CrossRef
27.
go back to reference Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. The Lancet. 2020;396(10247):313–9.CrossRef Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. The Lancet. 2020;396(10247):313–9.CrossRef
28.
go back to reference Soriano V, Meiriño R, Corral O, Guallar MP. Severe acute respiratory syndrome coronavirus 2 antibodies in adults in Madrid, Spain. Clin Infect Dis. 2021;72(6):1101–12.CrossRef Soriano V, Meiriño R, Corral O, Guallar MP. Severe acute respiratory syndrome coronavirus 2 antibodies in adults in Madrid, Spain. Clin Infect Dis. 2021;72(6):1101–12.CrossRef
29.
go back to reference Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al. Estimated community seroprevalence of SARS-CoV-2 antibodies—two Georgia counties, 28 April–3 May 2020. MMWR Morb Mortal Wkly Rep. 2020;69(29):965–70.CrossRef Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al. Estimated community seroprevalence of SARS-CoV-2 antibodies—two Georgia counties, 28 April–3 May 2020. MMWR Morb Mortal Wkly Rep. 2020;69(29):965–70.CrossRef
30.
go back to reference Menachemi N, Yiannoutsos CT, Dixon BE, Duszynski TJ, Fadel WF, Wools-Kaloustian KK, et al. Population point prevalence of SARS-CoV-2 infection based on a statewide random sample—Indiana, April 25–29, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(29):960–4.CrossRef Menachemi N, Yiannoutsos CT, Dixon BE, Duszynski TJ, Fadel WF, Wools-Kaloustian KK, et al. Population point prevalence of SARS-CoV-2 infection based on a statewide random sample—Indiana, April 25–29, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(29):960–4.CrossRef
31.
go back to reference Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Eurosurveillance. 2020;25(24):2001031.CrossRef Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Eurosurveillance. 2020;25(24):2001031.CrossRef
32.
go back to reference Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet. 2020;396(10250):535–44.CrossRef Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet. 2020;396(10250):535–44.CrossRef
33.
go back to reference Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol. 2020;92(10):2050–4.CrossRef Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol. 2020;92(10):2050–4.CrossRef
34.
go back to reference Haq M, Rehman A, Ahmad J, Zafar U, Ahmed S, Khan MA, Naveed A, Rajab H, Muhammad F, Naushad W, Aman M. SARS-CoV-2: big seroprevalence data from Pakistan—is herd immunity at hand? Infection. 2021;49(5):983–8.CrossRef Haq M, Rehman A, Ahmad J, Zafar U, Ahmed S, Khan MA, Naveed A, Rajab H, Muhammad F, Naushad W, Aman M. SARS-CoV-2: big seroprevalence data from Pakistan—is herd immunity at hand? Infection. 2021;49(5):983–8.CrossRef
35.
go back to reference Rudberg AS, Havervall S, Månberg A, Falk AJ, Aguilera K, Ng H, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat Commun. 2020;11(1):1–8.CrossRef Rudberg AS, Havervall S, Månberg A, Falk AJ, Aguilera K, Ng H, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat Commun. 2020;11(1):1–8.CrossRef
36.
go back to reference Tadj A, Lahbib SS. Our overall current knowledge of COVID 19: an overview. Micro Infec Chemotherapy. 2021;1: e1262.CrossRef Tadj A, Lahbib SS. Our overall current knowledge of COVID 19: an overview. Micro Infec Chemotherapy. 2021;1: e1262.CrossRef
Metadata
Title
Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms
Authors
Wajiha Javed
Syed Hussain Baqar Abidi
Jaffer Bin Baqar
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07461-9

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue